Literature DB >> 22917779

Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.

Xue-Qing Zhang1, Xiaoyang Xu, Nicolas Bertrand, Eric Pridgen, Archana Swami, Omid C Farokhzad.   

Abstract

The application of nanotechnology to personalized medicine provides an unprecedented opportunity to improve the treatment of many diseases. Nanomaterials offer several advantages as therapeutic and diagnostic tools due to design flexibility, small sizes, large surface-to-volume ratio, and ease of surface modification with multivalent ligands to increase avidity for target molecules. Nanomaterials can be engineered to interact with specific biological components, allowing them to benefit from the insights provided by personalized medicine techniques. To tailor these interactions, a comprehensive knowledge of how nanomaterials interact with biological systems is critical. Herein, we discuss how the interactions of nanomaterials with biological systems can guide their design for diagnostic, imaging and drug delivery purposes. A general overview of nanomaterials under investigation is provided with an emphasis on systems that have reached clinical trials. Finally, considerations for the development of personalized nanomedicines are summarized such as the potential toxicity, scientific and technical challenges in fabricating them, and regulatory and ethical issues raised by the utilization of nanomaterials.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22917779      PMCID: PMC3517211          DOI: 10.1016/j.addr.2012.08.005

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  217 in total

Review 1.  Nanoparticles: potential biomarker harvesters.

Authors:  David H Geho; Clinton D Jones; Emanuel F Petricoin; Lance A Liotta
Journal:  Curr Opin Chem Biol       Date:  2006-01-18       Impact factor: 8.822

2.  HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation.

Authors:  Elisabetta Gianasi; Robert G Buckley; John Latigo; Mo Wasil; Ruth Duncan
Journal:  J Drug Target       Date:  2002-11       Impact factor: 5.121

3.  Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.

Authors:  E T Dams; P Laverman; W J Oyen; G Storm; G L Scherphof; J W van Der Meer; F H Corstens; O C Boerman
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

4.  Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.

Authors:  J M Meerum Terwogt; W W ten Bokkel Huinink; J H Schellens; M Schot; I A Mandjes; M G Zurlo; M Rocchetti; H Rosing; F J Koopman; J H Beijnen
Journal:  Anticancer Drugs       Date:  2001-04       Impact factor: 2.248

Review 5.  Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.

Authors:  Janos Szebeni; Franco Muggia; Alberto Gabizon; Yechezkel Barenholz
Journal:  Adv Drug Deliv Rev       Date:  2011-07-14       Impact factor: 15.470

6.  HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.

Authors:  T Minko; P Kopecková; V Pozharov; J Kopecek
Journal:  J Control Release       Date:  1998-07-31       Impact factor: 9.776

7.  Size-dependent cytotoxicity of gold nanoparticles.

Authors:  Yu Pan; Sabine Neuss; Annika Leifert; Monika Fischler; Fei Wen; Ulrich Simon; Günter Schmid; Wolfgang Brandau; Willi Jahnen-Dechent
Journal:  Small       Date:  2007-11       Impact factor: 13.281

8.  Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging.

Authors:  Rolf Koole; Matti M van Schooneveld; Jan Hilhorst; Karolien Castermans; David P Cormode; Gustav J Strijkers; Celso de Mello Donegá; Daniel Vanmaekelbergh; Arjan W Griffioen; Klaas Nicolay; Zahi A Fayad; Andries Meijerink; Willem J M Mulder
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

9.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

Authors:  Yogesh B Patil; Suresh K Swaminathan; Tanmoy Sadhukha; Linan Ma; Jayanth Panyam
Journal:  Biomaterials       Date:  2009-10-01       Impact factor: 12.479

10.  Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes.

Authors:  Michael R McDevitt; Debjit Chattopadhyay; Barry J Kappel; Jaspreet Singh Jaggi; Scott R Schiffman; Christophe Antczak; Jon T Njardarson; Renier Brentjens; David A Scheinberg
Journal:  J Nucl Med       Date:  2007-07       Impact factor: 11.082

View more
  63 in total

1.  Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.

Authors:  Xue-Qing Zhang; Orli Even-Or; Xiaoyang Xu; Mariska van Rosmalen; Lucas Lim; Suresh Gadde; Omid C Farokhzad; Edward A Fisher
Journal:  Adv Healthc Mater       Date:  2014-08-22       Impact factor: 9.933

Review 2.  Unintended effects of drug carriers: Big issues of small particles.

Authors:  Hamideh Parhiz; Makan Khoshnejad; Jacob W Myerson; Elizabeth Hood; Priyal N Patel; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

Review 3.  Biomimetic nanoparticle technology for cardiovascular disease detection and treatment.

Authors:  Joon Ho Park; Diana Dehaini; Jiarong Zhou; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Nanoscale Horiz       Date:  2019-06-28       Impact factor: 10.989

4.  Cyclodextrin-based targeting strategies for tumor treatment.

Authors:  Juan-Juan Yin; Zhi-Wei Zhou; Shu-Feng Zhou
Journal:  Drug Deliv Transl Res       Date:  2013-08       Impact factor: 4.617

Review 5.  Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine.

Authors:  Zhihang Chen; Balaji Krishnamachary; Jesus Pachecho-Torres; Marie-France Penet; Zaver M Bhujwalla
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-10-23

Review 6.  Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development.

Authors:  Meghana Rawal; Amit Singh; Mansoor M Amiji
Journal:  Pharm Res       Date:  2019-09-03       Impact factor: 4.200

7.  Nanomedicines for Endothelial Disorders.

Authors:  Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal:  Nano Today       Date:  2015-12-01       Impact factor: 20.722

8.  An apolipoprotein-enriched biomolecular corona switches the cellular uptake mechanism and trafficking pathway of lipid nanoparticles.

Authors:  L Digiacomo; F Cardarelli; D Pozzi; S Palchetti; M A Digman; E Gratton; A L Capriotti; M Mahmoudi; G Caracciolo
Journal:  Nanoscale       Date:  2017-11-16       Impact factor: 7.790

Review 9.  Nanoformulation of natural products for prevention and therapy of prostate cancer.

Authors:  Vanna Sanna; Imtiaz A Siddiqui; Mario Sechi; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2012-11-29       Impact factor: 8.679

Review 10.  Folate-conjugated gold nanoparticle as a new nanoplatform for targeted cancer therapy.

Authors:  Hadi Samadian; Samira Hosseini-Nami; Seyed Kamran Kamrava; Habib Ghaznavi; Ali Shakeri-Zadeh
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-21       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.